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Abstract
Objectives To assess the suitability of the Breast Imaging
Reporting and Data System (BI-RADS) as a quality assess-
ment tool in the Dutch breast cancer screening programme.
Methods The data of 93,793 screened women in the Amster-
dam screening region (November 2005–July 2006) were
reviewed. BI-RADS categories, work-up, age, final diagnosis
and final TNM classification were available from the screen-
ing registry. Interval cancers were obtained through linkage
with the cancer registry. BI-RADSwas introduced as a pilot in
the Amsterdam region before the nationwide introduction of
digital mammography (2009–2010).
Results A total of 1,559 women were referred to hospital
(referral rate 1.7 %). Breast cancer was diagnosed in 485
women (detection rate 0.52 %); 253 interval cancers were
reported, yielding a programme sensitivity of 66 % and
specificity of 99 %. BI-RADS 0 had a lower positive pre-
dictive value (PPV, 14.1 %) than BI-RADS 4 (39.1 %) and
BI-RADS 5 (92.9 %; P<0.0001). The number of invasive
procedures and tumour size also differed significantly be-
tween BI-RADS categories (P<0.0001).
Conclusion The significant differences in PPV, invasive
procedures and tumour size match with stratification into
BI-RADS categories. It revealed inter-observer variability
between screening radiologists and can thus be used as a
quality assessment tool in screening and as a stratification
tool in diagnostic work-up.
Key Points
• The BI-RADS atlas is widely used in breast cancer screen-
ing programmes.
• There were significant differences in results amongst dif-
ferent BI-RADS categories.
• Those differences represented the radiologists’ degree of
suspicion for malignancy, thus enabling stratification of
referrals.
• BI-RADS can be used as a quality assessment tool in
screening.
• Training should create more uniformity in applying the BI-
RADS lexicon.
Keywords BI-RADS . Positive predictive value . Quality
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Introduction
The Dutch nationwide breast cancer screening programme
was introduced in 1989 and fully implemented in 1997.
Originally, the target population consisted of women aged
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50–69 but in 1998 the upper age limit was raised to 75 [1].
Every 2 years, eligible women are invited for mammographic
screening. Since the start of the programme, over 13 million
screening examinations have been performed and 56,000
breast cancers have been detected [2]. In The Netherlands,
women with a positive screening examination are referred to
their general practitioner and subsequently to a hospital of
their choice for further assessment [3]. Diagnostic work-up
after referral is not an integrated part of the screening
programme like in many other countries but is carried out in
general or academic hospitals (a reason to avoid the more
common international term ‘recall’). Additional imaging
(e.g. ultrasound and/or magnification views) is also performed
in these hospitals and only when necessary, additional
imaging is followed by a biopsy.
The National Expert and Training Centre for Breast Cancer
Screening (NETCB) aims to safeguard and constantly im-
prove the quality of the breast cancer screening programme
[4]. Recurrent site visits are performed as part of the national
quality assurance programme. During these site visits, the
NETCB observed cases of miscommunication between
screening radiologists, general practitioners and hospital spe-
cialists. As a result, the national guideline “breast cancer” [3]
recommended the use of the Breast Imaging Reporting and
Data System (BI-RADS) [5] in the screening programme and
this was made compulsory by the National Institute for Public
Health and the Environment (RIVM) in 2008. The RIVM
coordinates and directs the population screening programmes
on behalf of the Ministry of Public Health, Welfare and
Sports (VWS).
The BI-RADS atlas is developed by the American College
of Radiology (ACR) to improve communication between
physicians, and provides standardised mammographic report-
ing, breast imaging terminology, a report organisation and a
classification system [5]. It also provides a complete follow-
up and outcome monitoring system that allows a screening or
clinical practice to determine performance outcomes such as
the positive predictive value (PPV) and the percentage of
small and node negative cancers. These quality assurance data
are meant to improve the quality of patient care [5]. Several
studies have shown that the use of BI-RADS in a clinical
setting can be useful in predicting the presence of malignancy
and improving the choice and efficiency of further necessary
examinations [6–9]. It has been widely adopted in clinical
practice throughout the world. BI-RADS is also implemented
in screening programmes in the United States [10] and
Europe [11, 12].
We retrospectively assessed the introduction of BI-RADS
in the Amsterdam screening region, a pilot study before the
nationwide introduction. The purpose of this study was to
evaluate its feasibility, inter-observer agreement and its
ability to stratify referred women according to the chance
of malignancy, tumour size and follow-up procedures.
Furthermore, we identified interval cancers to assess the




The data of 93,793 women (aged 49–75) who participated in
the programme of the Amsterdam screening region (between
November 2005 and July 2006) were reviewed. Women
consented for the anonymous use of their data for research.
The mammograms are independently read by two certified
screening radiologists who must reach consensus about re-
ferral for further diagnostic assessment. If consensus is not
reached, a third radiologist will decide. The result of a
screening mammogram is classified as “suspicious” (these
women are referred for diagnostic work-up in a hospital) or
“not suspicious” (no diagnostic work-up is necessary).
Assessment and diagnosis
In most hospitals the mammograms of the referred women
were repeated and completed with ultrasound and/or mag-
nification views and, if necessary, biopsies were performed.
Information on each individual woman (age at diagnosis,
BI-RADS category, final TNM classification [UICC 2002],
the type of diagnostic work-up and final diagnosis) was
derived from the screening registry and cancer registry.
True-positive final diagnosis is defined as a carcinoma
found within 1 year after referral in the screening programme.
When there is no carcinoma found within one year after a
positive screening examination, it is called a false-positive
screening examination [1, 5]. The cases with a TP diagnosis
were classified as ductal carcinoma in situ (DCIS), <1 cm,
≥1 cm and X (indefinite).
Interval cancers
To assess the overall performance of the screening programme
and each unit separately (programme sensitivity and specific-
ity), we identified the number of interval cancers by linking
the screening registry to the regional cancer registry. Interval
cancers are breast cancers diagnosed in women within 2 years
after a negative screening examination. Positive matches were
manually checked to exclude screen-detected cases of a later
screening round [13].
Radiologists
In the Amsterdam screening region, four groups of screen-
ing radiologists (screenings units) are responsible for the
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evaluation of the mammographic examinations. On average,
a screening radiologist reads over 12,000 screening mam-
mograms per year. Screening radiologists did not receive a
dedicated training programme on how to use BI-RADS in
the screening programme. However, all of them were famil-
iar with the use of BI-RADS in a clinical setting.
BI-RADS
The ACR guidelines [5] define a negative screening exam-
ination as one that is negative or has benign findings (BI-
RADS categories 1 and 2) and a positive screening exami-
nation as one for which referral is initiated (BI-RADS
categories 0, 4 or 5; Table 1). BI-RADS 3 was initially
included in this pilot study. Although this category is neg-
ative, it suggests short interval follow-up and this is not
available in the Dutch screening setting. As suggested by
the ACR 2003 guidelines [5], this category was excluded at
the final nationwide introduction of BI-RADS in the screen-
ing. In this study, the group of 0 and 3 were reviewed and
was found to represent a normal mix of abnormalities with
low suspicion requiring additional (imaging) work-up. They
were therefore merged into BI-RADS 0.
Data analysis
To calculate the PPV of the BI-RADS categories, we used
the number of TP diagnoses among the total of referrals per
category × 100 %. Logistic regression analysis was used to
estimate the influence of age together with BI-RADS out-
come on the PPV. Variation in PVV among screening units
was also taken into consideration. Data were analysed
with the statistical package R (version 2.8.1) [14].
Results were expressed in terms of odds ratios (OR) with
95 % confidence intervals (CI) and P values. The ACR
defines sensitivity as the probability of detecting a cancer
when a cancer exists and specificity as the probability of




Between 1 November 2005 and 30 June 2006, 93,793
women participated in the screening programme for breast
cancer in the Amsterdam region and 1,559 women were
referred to a hospital for diagnostic work-up (referral rate
1.7 %). Thirty-four women were referred for possible bilat-
eral breast cancers; therefore the total number of breasts
referred in this period was 1,593. Data on eight referrals
without final diagnosis were excluded from the analysis.
Another 39 referrals were excluded because the BI-RADS
classification of the screening examination was not avail-
able. One case was retrospectively classified as a technical
failure with extreme underexposure on one side in a very
large breast. This case was therefore excluded from further
analysis, leaving 1,545 referred breasts in 1,511 women in
the analysis.
All referred women went to hospital for diagnostic work-
up; 357 (23 %) referrals were first screens, while 1,189
(76 %) came from subsequent screens. The average age of
the women was 59 (SD 7.7). Women in the first screening
cycle were on average 10 years younger than the overall age
of woman in subsequent screens.
Screening performance
The programme sensitivity was 66 % (95 % CI 63–69),
based on 485 true positives and 253 false negatives. The
programme specificity was 99 % (95 % CI 99–99), based on
91,995 true negatives and 1,060 false positives (Table 2).
The programme sensitivity of the screening units ranged
between 62-68 %, whereas the programme specificity of
the screening units was more than 99 % for all.
BI-RADS, breast cancer and follow-up
Of the 1,545 referrals, 811 were assigned BI-RADS category
0 (53 %), 578 BI-RADS category 4 (37 %) and 156 BI-
RADS category 5 (10 %) (Table 3). Of the referrals, 485
(31 %) were true positives and 1,060 (69 %) were false
positives. The PPVof BI-RADS 0 was 14 % (95 % CI: 12–
17), of BI-RADS 4 39% (95%CI 35–43) and of BI-RADS 5
93 % (95 % CI 88–96) (Table 3).
Table 3 also shows the tumour size of cases with a true-
positive diagnosis. Tumour size was positively relatedwith the
BI-RADS category. Although the positive predictive value of
BI-RADS 0 was relatively low, this group still accounted for
the highest number (38 %) of smaller tumours (<1 cm), while
78 % of the BI-RADS 5 tumours were larger than 1 cm.
Diagnostic work-up differed for each BI-RADS category.
The most invasive measures were performed in BI-RADS 5









2 Benign finding(s) No
4 Suspicious abnormality, not the
classic appearance for malignancy,
but has a reasonable possibility of
being malignant
Yes
5 Highly suggestive of malignancy Yes
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(96 %) (Table 3). A biopsy procedure was performed in
47 % of the women with BI-RADS 0 and 53 % of the
women with BI-RADS 0 received only non-invasive imag-
ing procedures.
Factors associated with the PPV of BI-RADS
The PPV of BI-RADS increased with increasing age (see
Table 4). There is also a relationship between age and the
probability of having a TP assessment, stratified by BI-
RADS category. This is shown in Fig. 1 (non-parametric
regression [LOESS] estimates).
Another factor associated with the PPV is the significant
difference (P<0.001) in assigning BI-RADS categories
between the four screening units (Table 5). Assigning BI-
RADS 0 varied from 27 % to 72 % and BI-RADS 4 from
20 % to 62 %, while BI-RADS 5 showed little difference
(from 8 % to 14 % of the cases).
Discussion
In this retrospective study we evaluated the use of the BI-
RADS final assessment in the Dutch breast cancer screening
setting. The differences in PPV, invasive procedures and
tumour size between the BI-RADS categories confirm that
stratification of the referred cases ties in with the radiolog-
ist’s level of suspicion. The number of more subtle and
favourable tumours in the BI-RADS 0 category stresses
the importance of referring also the less suspicious and more
subtle abnormalities to hospital for further assessment. At
the same time the assignment of the BI-RADS categories
revealed significant differences between screening units in
this study.
The difference in BI-RADS application between units did
not result in differences in interval cancers. The overall
performance of the Amsterdam screening region is some-
what lower than the national screening programme (71 %
until 2004 [1]) which may be explained by the fact that
Amsterdam is an urban region [15]. Because of a higher
number of referrals and the introduction of digital mammog-
raphy, the detection rate in The Netherlands increased every
year from 4.9 in 2005 to 5.7 in 2009. The effect on the
number of interval carcinomas will become evident in the
next couple of years. Until the introduction of BI-RADS in
the screening, the screening radiologists received regular
feedback on their performance on a local basis. As peer
review and outcome monitoring will increase the quality
of patient care [5], the outcomes of all women referred and
interval carcinomas detected were periodically evaluated.
However, this system of outcome monitoring did not reveal
the inter-observer variability between the four screening
units and inconsistency in applying the BI-RADS lexicon,
in our study mainly BI-RADS 0 and 4. Only in the relatively
small group of BI-RADS 5 did we find, as expected, a
substantial agreement. We also found that in larger numbers
of screening examinations, BI-RADS is able to stratify the
referred women adequately.
Table 2 Screening outcomes of the screening programme in the Amsterdam region (The Netherlands)
Breast cancer (n) No breast cancer (n) Total Predictive value (95 % CI)
Referral (n) 485 (TP) 1,060 (FP) 1,545 PPV031 % (29–34)
No referral (n) 253 (FN) 91,995 (TN) 92,248 NPV 0 99 % (99–99)
Total 738 93,055 93,793
Sensitivity066 % Specificity099 %
TP true positive screening examination, FP false positive screening examination, FN false negative screening examination, TN true negative
screening examination, FN false negative screening examination, TN true negative screening examination, PPV positive predictive value, NPV
negative predictive value
Sensitivity0485/(485+253)066 % (95 % CI: 63-69), specificity091,995/(1,060+91,995)099 % (95 % CI 99-99)
Table 3 Diagnostic work-up and tumour size according to BI-RADS category
BI-RADS n Breast cancer (n) PPV (%) Pathology (%) DCIS (%) <1 cm (%) ≥1 cm (%) Imaging only (%)
Screen detected Interval cancers
0 811 114 - 14.1 384 (47.3) 26 (22.8) 43 (37.7) 45 (39.5) 427 (52.7)
4 578 226 - 39.1 366 (63.3) 43 (19.0) 78 (34.5) 105 (46.5) 212 (36.7)
5 156 145 - 92.9 149 (95.5) 6 (4.2) 26 (17.9) 113 (77.9) 7 (4.5)
Total 1,545 485 - 31.4 899 (58.2) 75 (15.5) 147 (30.3) 263 (54.2) 646 (41.8)
1/2 92,247 - 253 - - 20 (7.9) 33 (13.0) 200 (79.1) -
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Several other studies [16–18] also showed a substantial
inter-observer variation in assigning the BI-RADS catego-
ries. This can possibly be explained by a lack of dedicated
BI-RADS training and local variation in its application.
Even expert radiologists have limited consistency in using
the BI-RADS assessment categories [19], but according to
Berg [20] proper training and continuing application may
improve this. As the preliminary results of this study be-
came available early, the NETBC developed a dedicated BI-
RADS training programme for all screening radiologists.
This training programme significantly improved the inter-
observer variation among new screening radiologists [21].
Training will also create more uniformity in applying the BI-
RADS lexicon by the screening radiologists as described in
several studies [20, 22, 23].
The introduction of the BI-RADS in the screening setting
functions as an interesting benchmark indicator in our new
continuous medical quality audit, especially on a local level
it revealed significant differences between units. Therefore
we believe that BI-RADS can be used as a quality assess-
ment tool for screening radiologists.
Consistent use of BI-RADS is also of importance to those
who are involved in the diagnostic work-up. Screening
Table 4 The influence of BI-RADS and age on positive predictive
value, expressed as odds ratios from logistic regression analysis
na PPV (%)b OR (CI 95 %)
BI-RADS category
0 811 114 (14.1) 1 -
4 578 226 (39.1) 4.6 (3.4-6.2)
5 156 145 (92.9) 93 (47–183)
Age
50-54 528 104 (19.7) 1 -
55-59 307 84 (27.4) 1.4 (0.94-2.1)
60-67 396 154 (39.6) 2.4 (1.7-3.5)
68-76 314 143 (45.5) 3.1 (2.2-4.6)
OR odds ratio, CI confidence interval, PPV positive predictive value
a Total number01,545
b Total number0484
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mammography is effective for the early detection of breast
cancer. However, most referred cases prove to be benign
after further assessment either with only imaging (additional
views and ultrasound) or with additional biopsy procedures.
In our study, more than half of the women with BI-RADS 0
could be dismissed after only imaging procedures at the
radiology department. Instead, they visited the multidisci-
plinary team which is mandatory according to our national
breast cancer guidelines [3]. As BI-RADS differentiates
between cases with a high (BI-RADS 4 or 5) or low suspicion
(BI-RADS 0) for malignancy, it provides knowledge of the
chance of malignancy and can thus determine the urgency and
type of further assessment. The BI-RADS 0 cases could then
be assessed separately from the BI-RADS 4 and 5 cases, for
instance along a “quick assessment route” to the hospital
radiology departments. Policy makers should be aware of
the possibilities of BI-RADS as a stratification tool and con-
sider reviewing the current policies as it could possibly reduce
waiting times, costs and unnecessary anxiety [24].
There are several factors that might have influenced the
results of this study. Firstly, BI-RADS categories 0, 4 and 5
in our study are assigned on the basis of a screening mam-
mogram only. Thus, they represent no final findings and
further imaging work-up still needs to be performed. This
might have been reflected in a different mix of BI-RADS 0
and 4 for the referred cases in our study compared with
studies in the United States or other European countries [10,
11]. This decision how to perform the diagnostic work-up is
the responsibility of the clinical radiologist who is not
necessarily the same person as the screening radiologist.
Secondly, international comparison is difficult due to addi-
tional differences in characteristics of the screening pro-
grammes, including the criteria for referral. The referral
rate in The Netherlands is still among the lowest worldwide
[25–27]. Therefore, comparing our results with studies from
the United States or other countries in Europe is therefore
not straightforward; it has led to differences in the PPV of
BI-RADS in our results compared with the PPV in other
studies. Taplin [10] described a PPVof BI-RADS category 4
of 16.7 % (versus 39 % in our study) and a PPV of BI-
RADS category 5 of 68.4 % (versus 93 % in our study). Our
results were comparable with those from another study from
The Netherlands, that reported a PPVof BI-RADS category
4 of 40 % and a BI-RADS category 5 of 100 % in a
screening population [6].
In conclusion, the significant differences we found in
PPV, invasive procedures and tumour size match with the
stratification into BI-RADS categories and thus represent
the radiologists’ degree of suspicion for malignancy. BI-
RADS can therefore be used as a quality assessment tool
in the screening and stratification tool in the diagnostic
work-up. Training of screening radiologists should create
more uniformity in the application of BI-RADS.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribution,
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